TRAD CHI MED released its interim results, with a loss attributable to shareholders of 108 million yuan, turning from profit to loss year-on-year
TRAD CHI MED released its interim results for the period ending June 30, 2025, with a revenue of 7.463 billion yuan, a year-on-year decrease of 11%. The company's loss attributable to shareholders was 108 million yuan, compared to a profit of 211 million yuan in the same period last year, with a basic loss per share of 2.14 cents. The decline in revenue was mainly due to the increased proportion of traditional Chinese medicine formula granules in the centralized procurement business and intensified market competition. At the same time, the group optimized its business structure, reducing low-margin and high-risk operations, leading to a decrease in sales revenue
According to the Zhitong Finance APP, China Traditional Chinese Medicine (00570) released its interim results for the six months ending June 30, 2025, reporting a revenue of 7.463 billion yuan, a year-on-year decrease of 11%; the loss attributable to shareholders was 108 million yuan, compared to a profit of 211 million yuan in the same period last year; basic loss per share was 2.14 cents.
The announcement stated that the decline in revenue was mainly due to the significant increase in the proportion of the traditional Chinese medicine formula granule centralized procurement business and intensified market competition, leading to a decrease in sales revenue during the period. At the same time, the group is actively promoting the optimization of its business structure, focusing on the development of local varieties and advantageous varieties in the production and operation of traditional Chinese medicine materials, strategically reducing low-margin and high-risk businesses, resulting in a year-on-year decrease in revenue; the traditional Chinese medicine health sector has suspended some homogenized and non-competitive product lines and businesses, which also contributed to a decline in revenue during the period
